Tirzepatide
A$399
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in metabolic health, weight management and blood sugar regulation. It works through two complementary incretin pathways to support appetite regulation and metabolic function. Suitability depends on medical history, medications, glucose status and practitioner review.
Strength
15 mg
Volume
2 mL
Format
Dual-chamber pen
Administration
Subcutaneous injection
Storage
Refrigerated 2–8°C
Product code
TRZ15
Overview
Tirzepatide is a novel dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. This dual mechanism supports blood glucose regulation, appetite modulation and energy balance through complementary pathways.
It has been studied in large clinical trials for type 2 diabetes and weight management. FDA-approved as Mounjaro for type 2 diabetes. Individual responses, safety profiles and appropriate use depend significantly on baseline health status, concurrent medications and monitoring.
How it works
Signal
Tirzepatide binds to GIP receptors and GLP-1 receptors, activating two complementary nutrient-sensing pathways simultaneously.
Response
Insulin secretion increases in a glucose-dependent manner, glucagon is suppressed, gastric emptying slows, and appetite signals are reduced.
Monitoring
HbA1c, fasting glucose, kidney function, heart rate, gastrointestinal symptoms and body weight should be reviewed regularly.
Suitability, cautions and safety
Important: This information is for educational purposes only. It does not replace assessment, diagnosis or medical advice from a qualified clinician. Suitability varies by individual health history, medications and circumstances.
Personal or family history of medullary thyroid cancer or MEN2
GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumours in animal studies. Not recommended with this history.
Pancreatic disease or history of pancreatitis
GLP-1 agonists have been associated with pancreatitis. Symptoms of pancreatitis require immediate medical review.
Gallbladder disease
GLP-1 related compounds have been associated with gallbladder events including cholelithiasis.
Diabetic retinopathy
Rapid glucose improvement may temporarily worsen retinopathy. Eye review recommended.
Severe kidney or liver impairment
Dose adjustment or avoidance may be required. Specialist review needed.
Eating disorders
Appetite suppression mechanisms require careful assessment in the context of any history of disordered eating.
Pregnancy, breastfeeding or trying to conceive
Not recommended. Discontinue use at least 2 months before attempting conception.
Planned surgery
Gastric emptying effects may affect anaesthesia management. Discuss with your surgical team.
Answer each question honestly. If you answer Yes to any question, we recommend discussing this compound with a qualified clinician before proceeding.
Do you have a personal or family history of medullary thyroid cancer or MEN2 syndrome?
Have you ever had pancreatitis or do you have a diagnosed pancreatic condition?
Have you had gallbladder problems, gallstones or cholecystitis?
Are you pregnant, breastfeeding or trying to conceive?
Do you have kidney disease or significantly reduced kidney function?
Do you have surgery planned?
Do you have any history of disordered eating or an eating disorder?
If you have any of the following, discuss with a clinician before purchasing or using this product
- Persistent or severe abdominal pain (possible pancreatitis)
- Nausea, vomiting or diarrhoea that does not resolve
- Yellowing of skin or eyes
- Rapid heartbeat
- Symptoms of low blood sugar (shakiness, sweating, confusion)
- Significant unexplained weight loss beyond expectations
- Vision changes
Adverse effects and safety signals
Common effects
Generally mild and often resolve without intervention. Monitor and report if persistent.
- Nausea — Very common, particularly during dose escalation. Usually improves over time.
- Vomiting
- Diarrhoea or constipation
- Reduced appetite — Expected mechanism effect.
- Injection-site reaction
- Fatigue
Discuss promptly with a clinician
If any of the following occur, stop use and contact your prescribing practitioner.
- Persistent or severe vomiting preventing adequate nutrition
- Persistent severe abdominal pain
- Symptomatic low blood sugar
- Signs of gallbladder problems — right upper abdominal pain
- Rapid heartbeat that persists
- Significant dehydration
Seek emergency help immediately
If you experience any of the following, call emergency services (000 in Australia) immediately. These may be signs of a serious allergic reaction or medical emergency.
- Difficulty breathing or throat tightening
- Facial, lip or tongue swelling
- Widespread hives or rash
- Fainting or collapse
- Severe continuous abdominal pain radiating to the back (possible pancreatitis)
Important: Before use, tell your practitioner if you have ever had an allergic reaction to any peptide, injection product or medicine. Allergic reactions can occur even with first use. I understand that I should seek urgent medical help if I experience signs of a serious allergic reaction.
Medications and interactions
Medicines and treatments to discuss
Tirzepatide significantly affects glucose metabolism. If you use insulin or other glucose-lowering medications, dose adjustments may be required. Gastric emptying effects can alter the absorption of oral medications taken simultaneously. Disclose all diabetes medications, blood thinners, cardiovascular drugs, supplements and other peptides.
Bloodwork and monitoring
The following tests may be considered at baseline and during use. Your Zenith practitioner will advise on what is relevant for you.
Baseline (before use)
- HbA1c
- Fasting glucose
- Kidney function
- Liver function
- Lipid profile
- Full blood count
Follow-up (during use)
- HbA1c
- Fasting glucose
- Kidney function
- Lipid profile
Administration
Administer once weekly by subcutaneous injection on the same day each week.
Inject into the abdomen, thigh or upper arm. Rotate sites.
Dose is typically escalated gradually over several weeks — follow your protocol card.
If a dose is missed by more than 4 days, skip it and resume the next scheduled dose.
Use a fresh needle for each injection and dispose of sharps safely.
Storage and handling
Store refrigerated at 2–8°C.
Once activated, use within 28 days when kept refrigerated.
Do not freeze.
Can be stored at room temperature (up to 30°C) for a maximum of 21 days if required.
Protect from direct light.
Frequently asked
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in metabolic health and weight management. It is FDA-approved as Mounjaro for type 2 diabetes.
Gastric emptying is slowed, which can affect absorption of oral medications. Your practitioner will advise on any required adjustments.
Individual responses vary significantly. Blood sugar effects may appear early; metabolic and weight responses typically build over weeks to months with gradual dose escalation.
Tirzepatide is approved for type 2 diabetes management. However, careful monitoring and medication adjustment with your treating clinician is essential.
Regulatory and classification note: Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes. Use for weight management is approved in some jurisdictions. Compounded supply requires practitioner review. This information is educational only.
Regulatory & safety information
Tirzepatide is supplied subject to suitability assessment and applicable UAE regulatory requirements. Information provided is general and is not a substitute for professional medical advice, diagnosis or treatment.
Always consult a qualified healthcare professional before starting, changing or stopping any product, particularly if you are pregnant, breastfeeding, under 18, or managing a medical condition.
Why treatment isn't self-selected
Treatment decisions need context.
Selecting a treatment option is the starting point. What's clinically appropriate for you is determined by three things together.
Your bloodwork
Relevant biomarkers help identify which treatment options may be appropriate — and which should be avoided.
Your health history
Existing conditions, medications and goals are considered alongside your results, not in isolation.
Practitioner review
A licensed practitioner reviews every request before anything is approved, dosed or supplied.
Before you choose
Your bloodwork can change the conversation.
Recent bloodwork gives your practitioner more to work with — helping identify what may be appropriate, what should be avoided, and where a different option might be better suited to your results.
Already uploaded results? Your practitioner reviews them alongside any treatment request — no need to repeat information.
Optional at this stage. Required before final approval.
Ready to move forward?
Three ways to continue.
Upload your bloodwork
Already have recent results? Upload them so your practitioner can review your treatment request in context.
Purchase a blood test
No recent results? Order an at-home Zenith blood test to establish your baseline before choosing treatment.
Start your assessment
Begin the health assessment now — you can add bloodwork and treatment selections at any stage.
Purchase
Tirzepatide
Supplied following assessment, bloodwork and practitioner review.
Price
A$399
Ready to start?
Complete an assessment and get access to Tirzepatide through a tailored protocol.